Jubbonti ® (denosumab-bbdz) and Wyost ® (denosumab-bbdz), interchangeable biosimilars to Prolia ® (denosumab) and Xgeva ® (denosumab), respectively, are now available from Sandoz. The ...

The study will assess the number and severity of dose-limiting toxicities and adverse events. A new study will evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells ...

Phase 3 trial results suggest that adjuvant treatment with mitomycin and bacillus Calmette-Guérin (BCG) is as safe and effective as BCG alone for patients with high-risk non-muscle invasive bladder ...

An artificial intelligence-based tool identifies patients with high-risk, nonmetastatic prostate cancer (PCa) who would most likely benefit from treatment intensification, an investigator reported at ...

Investigators presented an interim analysis of the phase 3 ENLIGHTED trial of photodynamic therapy in patients with low-grade upper-tract urothelial cancer.

The first trial of adjuvant platinum-based chemotherapy plus paclitaxel in patients with high-risk penile cancer provided some insights.

Engaging in leisure-time MVPA linked to improved survival for various cancer types including bladder, breast, colon. (HealthDay News) — Engaging in leisure-time moderate- to vigorous-intensity ...

Medical AI tools for clinicians and patients have advantages and disadvantages, including implicit bias in triage and virtual urgent care.

PARP inhibitors demonstrate synergy with radiation, so investigators tested the efficacy and safety of olaparib plus radium-223 in patients with mCRPC and bone metastases in a phase 2 trial.

Rapid reduction of glucocorticoid (GC) doses to 7.5 mg/day or less within 6 months may not worsen renal outcomes or increase relapse in patients with proliferative lupus nephritis (LN), recent study ...

Direct oral anticoagulants suggested over standard of care anticoagulants for pediatric patients with venous thromboembolism. (HealthDay News) — In clinical guidelines issued by the American ...

Receipt of female hormones appeared to lead to protective vasodilation in nephrons. Male hormone use appeared to induce subclinical kidney stress. A prospective observational study of transgender ...